Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee; Mining past creatures’ DNA for future antibiotics

Taking stock of the drug industry, from the lab to the medicine chest

October 25, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Photo Illustration: Dom Smith/STAT; Photos: Yana Paskova/Getty Images; Drew Angerer/Getty Images, AP Photo/Keystone, Georgios Kefalas STAT+ | Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee The Swiss drug giant says Takeda is stonewalling efforts to review trade secrets taken by the former employee. By Ed Silverman Giant sloths and woolly mammoths: Mining past creatures' DNA for future antibiotics The hope is that the genes of extinct creatures — mammoths, Neanderthals, sloths – hold solutions to rising antibiotic resistance. By Jason Mast STAT+ | A controversial new study examines traditional Chinese medicine's potential cardiac benefits JAMA struggled with whether to publish a new study on potential cardiac benefits of tongxinluo, a traditional Chinese medicine compound. By Annalisa Merelli and Matthew Herper Suzanne KreiterGlobe staff STAT+ | Massachusetts biotechs seek to piggyback on weight loss drug boom In the wake of drugs like Ozempic, Massachusetts biotechs are seeking to elbow their way into the lucrative weight loss drug market. By Robert Weisman — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser